At the news
? NEUTRALIMPACT 5/10 PRESS-RELEASE filed Aug 6, 2026 at 07:30 ET
Lexicon Pharmaceuticals reported Q2 2026 revenue of $0.7M, down 97.6% from $28.9M a year ago due to the absence of a $27.6M Novo Nordisk licensing milestone, and a net loss of $31.8M ($0.07/share) vs net income of $3.3M a year ago. The key catalysts are the completion of SONATA-HCM enrollment (topline Q1 2027) and ZYNQUISTA NDA resubmission expected Q4 2026, with $190.6M cash providing runway through these events.
- Q2 2026 total revenue $0.7M vs $28.9M in Q2 2025 (included $27.6M licensing milestone from Novo Nordisk)
- Net loss $31.8M ($0.07/share) vs net income $3.3M ($0.01/share) in Q2 2025
- SONATA-HCM Phase 3 enrollment completed on time, substantially exceeding 500-patient target; topline results expected Q1 2027
- ZYNQUISTA NDA resubmission for type 1 diabetes anticipated Q4 2026
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access